Literature DB >> 21594581

Cross-sectional study of bone metabolism with nutrition in adult classical phenylketonuric patients diagnosed by neonatal screening.

Hironori Nagasaka1, Hirokazu Tsukahara, Tomozumi Takatani, Yoshitami Sanayama, Masaki Takayanagi, Toshihiro Ohura, Osamu Sakamoto, Tetsuya Ito, Mika Wada, Makoto Yoshino, Akira Ohtake, Tohru Yorifuji, Satoshi Hirayama, Takashi Miida, Hiroki Fujimoto, Hiroshi Mochizuki, Toshikazu Hattori, Yoshiyuki Okano.   

Abstract

The mechanism underlying the development of osteopenia or osteoporosis in longstanding phenylketonuria (PKU) remains to be clarified. We investigated the details of bone metabolism in 21 female and 13 male classical PKU patients aged 20-35 years. Vitamin D (VD), parathyroid hormone (PTH), bone turnover markers, and daily nutrient intake were examined. The patients had lower daily energy and protein intake than did the age-matched controls (22 women, 14 men), but their respective fat, VD, and calcium intake did not differ. Serum 1,25-dihydroxy VD and 25-hydroxy VD levels in female and male patient groups were significantly higher and lower than those in respective control groups (females, P < 0.001; males, P < 0.05 and P < 0.01, respectively). Serum intact PTH levels were significantly higher in the female patient group (P < 0.05). Urinary calcium levels in the patient groups were significantly higher than those of the control subjects (females, P < 0.001; males, P < 0.05). Bone resorption markers were significantly higher in patients than in controls, although bone formation markers were not different. Patient serum levels of osteoprotegerin-inhibiting bone resorption were significantly lower (females, P < 0.001; males, P < 0.01). None of the bone parameters correlated significantly with serum phenylalanine or nutrient intake. PKU patients exhibited lower VD status and more rapid bone resorption despite normal calcium-VD intakes. © The Japanese Society for Bone and Mineral Research and Springer 2011

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21594581     DOI: 10.1007/s00774-011-0276-6

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  30 in total

1.  Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice.

Authors:  S Yannicelli; D M Medeiros
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

2.  Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse?

Authors:  S Shefer; G S Tint; D Jean-Guillaume; E Daikhin; A Kendler; L B Nguyen; M Yudkoff; C A Dyer
Journal:  J Neurosci Res       Date:  2000-09-01       Impact factor: 4.164

3.  Serotonin and dopamine synthesis in phenylketonuria.

Authors:  H C Curtius; A Niederwieser; M Viscontini; W Leimbacher; H Wegmann; B Blehova; F Rey; J Schaub; H Schmidt
Journal:  Adv Exp Med Biol       Date:  1981       Impact factor: 2.622

4.  Total oxidative/anti-oxidative status and relation to bone mineral density in osteoporosis.

Authors:  Ozlem Altindag; Ozcan Erel; Neslihan Soran; Hakim Celik; Sahabettin Selek
Journal:  Rheumatol Int       Date:  2007-09-06       Impact factor: 2.631

5.  A longitudinal study of antioxidant status in phenylketonuric patients.

Authors:  Rafael Artuch; Catrina Colomé; Cristina Sierra; Nuria Brandi; Nilo Lambruschini; Jaume Campistol; Dolores Ugarte; Maria A Vilaseca
Journal:  Clin Biochem       Date:  2004-03       Impact factor: 3.281

6.  Decreased bone mineralization in children with phenylketonuria under treatment.

Authors:  L Hillman; C Schlotzhauer; D Lee; J Grasela; S Witter; S Allen; R Hillman
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

7.  Bone mineral status in children with phenylketonuria under treatment.

Authors:  A Al-Qadreh; K H Schulpis; H Athanasopoulou; C Mengreli; A Skarpalezou; I Voskaki
Journal:  Acta Paediatr       Date:  1998-11       Impact factor: 2.299

Review 8.  Oxidative stress, free radicals and bone remodeling.

Authors:  Giuseppe Banfi; Eugenio L Iorio; Massimiliano M Corsi
Journal:  Clin Chem Lab Med       Date:  2008       Impact factor: 3.694

9.  Antioxidant status in hyperphenylalaninemia.

Authors:  C Sierra; M A Vilaseca; D Moyano; N Brandi; J Campistol; N Lambruschini; F J Cambra; R Deulofeu; A Mira
Journal:  Clin Chim Acta       Date:  1998-08-10       Impact factor: 3.786

10.  RANK, RANKL and osteoprotegerin in bone biology and disease.

Authors:  H L Wright; H S McCarthy; J Middleton; M J Marshall
Journal:  Curr Rev Musculoskelet Med       Date:  2009-03-10
View more
  11 in total

1.  PKU patients on a relaxed diet may be at risk for micronutrient deficiencies.

Authors:  C Rohde; A von Teeffelen-Heithoff; A G Thiele; M Arelin; U Mütze; C Kiener; J Gerloff; C Baerwald; S Schultz; C Heller; A S Müller; W Kiess; S Beblo
Journal:  Eur J Clin Nutr       Date:  2013-11-20       Impact factor: 4.016

2.  A New View of Bone Loss in Phenylketonuria.

Authors:  Steven F Dobrowolski; Irina L Tourkova; Cayla R Sudano; Quitterie C Larrouture; Harry C Blair
Journal:  Organogenesis       Date:  2021-08-25       Impact factor: 2.316

Review 3.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

4.  Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet.

Authors:  Patrick Solverson; Sangita G Murali; Suzanne J Litscher; Robert D Blank; Denise M Ney
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

5.  Prevalence of neonatal hyperphenylalaninemia in yazd province, iran.

Authors:  Mahtab Ordooei; Majid Jafarizadeh; Mohsen Mirzaei; Hasan Ashoori; Ali Zare; Hossein Shojaeifar
Journal:  Iran J Med Sci       Date:  2015-05

Review 6.  Bone health in phenylketonuria: a systematic review and meta-analysis.

Authors:  Serwet Demirdas; Katie E Coakley; Peter H Bisschop; Carla E M Hollak; Annet M Bosch; Rani H Singh
Journal:  Orphanet J Rare Dis       Date:  2015-02-15       Impact factor: 4.123

7.  Status of nutrients important in brain function in phenylketonuria: a systematic review and meta-analysis.

Authors:  Gina A Montoya Parra; Rani H Singh; Aysun Cetinyurek-Yavuz; Mirjam Kuhn; Anita MacDonald
Journal:  Orphanet J Rare Dis       Date:  2018-06-26       Impact factor: 4.123

8.  Development of newborn screening connect (NBS connect): a self-reported patient registry and its role in improvement of care for patients with inherited metabolic disorders.

Authors:  Yetsa Osara; Kathryn Coakley; Aishwarya Devarajan; Rani H Singh
Journal:  Orphanet J Rare Dis       Date:  2017-07-19       Impact factor: 4.123

9.  Sex differences in body composition and bone mineral density in phenylketonuria: A cross-sectional study.

Authors:  Bridget M Stroup; Karen E Hansen; Diane Krueger; Neil Binkley; Denise M Ney
Journal:  Mol Genet Metab Rep       Date:  2018-02-03

10.  Bone Status in Patients with Phenylketonuria: A Systematic Review.

Authors:  María José de Castro; Carmela de Lamas; Paula Sánchez-Pintos; Domingo González-Lamuño; María Luz Couce
Journal:  Nutrients       Date:  2020-07-20       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.